Anti-Human Caspase-8 (Intermediate Domain)
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Rabbit Immunogen Purified Recombinant Human Caspase-8 (>98%) Product Concentration 0.5 mg/ml Formulation This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative. Storage and Handling This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day Ambient RRIDAB_2828385 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Rabbit Anti-Human Caspase-8 recognizes an epitope in the intermediate domain of mouse and human Caspase-8. This polyclonal antibody was purified using affinity chromatography. Background Caspases are a family of cysteine proteases that can be divided into the apoptotic and inflammatory caspase subfamilies. Unlike the apoptotic caspases, members of the inflammatory subfamily are generally not involved in cell death but are associated with the immune response to microbial pathogens.1,2 The apoptotic subfamily can be further divided into initiator caspases, which are activated in response to death signals, and executioner caspases, which are activated by the initiator caspases and are responsible for cleavage of cellular substrates that ultimately lead to cell death.3 Caspase-8 is an initiator caspase that was identified as a member of the Fas/APO-1 death-inducing signaling complex.4 The adaptor molecule FADD couples procaspase-8 to the Fas receptor death domain; subsequent oligomerization promotes procaspase-8 autoactivation.5 FLIP, a catalytically inactive caspase-8-like molecule inhibits these interactions and thus can inhibit apoptosis.6 caspase-8 presents a promising target to restore defective apoptosis programs in cancers in order to overcome resistance. PubMed References & Citations1. Martinon, F. and Tschopp, J. (2004) Cell 117:561-74. 2. Zhivotovsky, B. and Orrenius, S. (2005) Biochim. Biophys. Res. Comm. 331:859-67. 3. Wolf, BB. and Green, DR. (1999) J. Biol. Chem. 274:20049-52. 4. Dixit, VM. et al. (1996) Cell 85:817-27. Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
C1240 | |
C1241 | |
C1277 | |
C1278 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.